We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
MarketBeat on MSN1d
Gilead Sciences: 4 Reasons This Stock Has Much More To RiseCompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...
Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...
Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...
Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key ...
Bernstein raised the firm’s price target on Gilead (GILD) to $120 from $105 and keeps an Outperform rating on the shares. The firm notes Gilead ...
Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) saw some unusual options trading activity on Thursday. Stock investors bought 16,698 call options on the stock. This represents an increase of ...
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback